Investing.com - Karuna Therapeutics (NASDAQ: KRTX) reported fourth quarter EPS of $-3.01, $0.33 worse than the analyst estimate of $-2.68. Revenue for the quarter came in at $0.00 versus the consensus estimate of $862.42K.
Karuna Therapeutics's stock price closed at $318.94. It is up 67.27% in the last 3 months and up 66.50% in the last 12 months.
Karuna Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Karuna Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Karuna Therapeutics's Financial Health score is "fair performance".
Check out Karuna Therapeutics's recent earnings performance, and Karuna Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar